Lois Frankel, Representative
sell disclosed on 10 Oct 2023 via House STOCK Act disclosures
- Transaction value
- 1.001 US$
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Public company research profile
This public-disclosure research profile is not investment advice. It summarizes historical public filings, source links, confidence context, and hypothetical outcomes so readers can verify the evidence themselves.
Company research history
Bio-Rad Laboratories, Inc. Class A (BIO)
Source-transparent disclosure history for this company, built from public CopyWindow signals and previous hypothetical outcomes.
4 disclosures
2 insiders
0 cluster signals
0.0% avg. 30d outcome
Company facts
- Ticker / ISIN
- BIO / Not available
- Exchange
- Not available
- Country
- US
- Sector
- Not available
Disclosure history
Lois Frankel, Representative
buy disclosed on 28 Jul 2023 via House STOCK Act disclosures
- Transaction value
- 1.001 US$
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Lois Frankel, Representative
buy disclosed on 28 Jul 2023 via House STOCK Act disclosures
- Transaction value
- 1.001 US$
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Susie Lee, Representative
sell disclosed on 29 Dec 2022 via House STOCK Act disclosures
- Transaction value
- 1.001 US$
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%